"our" and "DexCom" refer to DexCom, Inc. unless the context requires otherwise.OverviewWe are a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for people with diabetes.
2006, we received approval from the U.S. Food and Drug Administration, or FDA, for our Short-Term Continuous Glucose Monitoring System, or STS™, and have launched this product
measurements and may be more costly to use.4Our StrategyOur objective is to become the leading provider of continuous glucose monitoring systems and related products to enable people with diabetes to more conveniently and
prospectus are the property of their respective owners.5The OfferingCommon stock offered:By DexCom, Inc.1,400,000 sharesBy the selling stockholders3,332,500 sharesTotal4,732,500 sharesCommon stock to be outstanding after this offering26,816,559 sharesUse of proceedsWe intend to use the net proceeds of this offering for manufacturing infrastructure, selling, general and administrative expenses, conducting clinical trials and other research and development, working capital and general corporate purposes.
Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations."Period from May 13,1999(inception)throughDecember 31,2005Years Ended December 31,200320042005(in thousands, except share and per share data)Statements of Operations Data:Costs and expenses:Research and development$8,935$12,179$25,497$61,609Selling, general and administrative1,2501,4405,14712,737Stock-based compensation:Research and development—2911,2731,564Selling, general and administrative—157513671Total costs and expenses10,18514,06732,43076,581Interest and other income, net2701211,6623,067Net loss(9,915)(13,946)(30,768)(73,514)Accretion to redemption value of Series B, Series C and Series D redeemable convertible preferred stock(3,234)(3,235)(122)(10,261)Net loss attributable to common stockholders$(13,149)$(17,181)$(30,890)$(83,775)Basic and diluted net loss per share attributable to common stockholders(1)$(6.06)$(7.51)$(1.63)Shares used to compute basic and diluted net loss per share attributable to common stockholders(1)2,169,9222,286,32018,994,208As of December 31, 2005ActualAs Adjusted(2)(in thousands)Balance Sheet Data:Cash, cash equivalents and short-term marketable securities$50,525$82,612Working capital43,93976,026Total assets56,72688,813Total stockholders' equity49,41281,499(1)See
STS is more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body,
cannot assure you that we will be able to develop and expand our manufacturing process and operations or obtain FDA and state agency approval of our new facility in a timely manner or at all.
clinical development and commercialization efforts could be delayed, which would harm our business and our results of operations.Our manufacturing operations are dependent upon third-party suppliers, making us vulnerable to supply problems and price fluctuations, which could harm our business.We rely on Flextronics International, Ltd. to manufacture and supply the receiver included as part of our continuous glucose monitoring systems and the circuit boards
In the United States, patients using existing single-point finger stick devices are generally reimbursed all or part of the product cost by Medicare or other third-party payors.
are developing or marketing short-term continuous glucose monitoring products that will compete directly with our STS.
a result, we may not be able to compete effectively against these companies or their products.No continuous glucose monitoring system, including our STS, has yet received FDA clearance as a replacement for single-point finger stick devices, and our products may never be
commercialize our continuous glucose monitoring systems under development, which could impair our financial position.Before submitting any additional PMA applications, we must successfully complete pre-clinical studies and clinical trials that we believe will demonstrate that the
unsuccessful in either filing or receiving FDA approval for additional PMA applications related to our glucose monitoring systems, our business strategy may have to be altered to rely solely on our
Any of these factors could harm our financial condition.Potential long-term complications from our STS or other continuous glucose monitoring systems under development may not be revealed by our clinical experience to
date.If unanticipated long-term side-effects result from the use of our STS or other glucose monitoring systems under development, we could be subject to
Failure to comply with new or existing laws or regulations could harm our business, financial condition and results of operations.Failure to obtain regulatory approval in foreign jurisdictions will prevent us from marketing our products abroad.Following commercial launch of our products in the United States, we may seek to market our products internationally.
our STS, develop additional continuous glucose monitoring products, expand our sales, marketing, manufacturing and corporate infrastructure.We
2006, we received approval from the U.S. Food and Drug Administration, or FDA, for our Short-Term Continuous Glucose Monitoring System, or STS, and have launched this product throughout
companies have attempted to address the limitations of single-point finger stick devices by developing continuous glucose monitoring systems.
companies have attempted to address the limitations of single-point finger stick devices by developing continuous glucose monitoring systems.
believe a significant market opportunity exists for a glucose monitoring system that provides continuous blood glucose information, including trends, and that is convenient and easy to use.The DexCom SolutionOur STS offers the following advantages to diabetes patients:•Convenience.We believe that convenience is the paramount factor in achieving widespread adoption of a continuous blood
believe a significant market opportunity exists for a glucose monitoring system that provides continuous blood glucose information, including trends, and that is convenient and easy to use.The DexCom SolutionOur STS offers the following advantages to diabetes patients:•Convenience.We believe that convenience is the paramount factor in achieving widespread adoption of a continuous blood
We believe the expertise gained in overcoming these problems will support the development of additional products beyond glucose monitoring.Our ProductsOn March 24, 2006, we received approval from the FDA for our STS, which includes a disposable sensor that can be inserted by a patient and used continuously for up to